Mira Pharmaceuticals (MIRA) Gains from Sales and Divestitures (2025)
Mira Pharmaceuticals (MIRA) posted Gains from Sales and Divestitures of $625000.0 for Q4 2025, up 11.11% sequentially from $562500.0 in Q3 2025.
Mira Pharmaceuticals (MIRA) Gains from Sales and Divestitures (2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 1 years of Gains from Sales and Divestitures data on file, last reported at $625000.0 in Q4 2025.
- Quarterly Gains from Sales and Divestitures changed N/A year-over-year to $625000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $625000.0 (changed N/A YoY) and the FY2025 annual result came in at $625000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures advanced to $625000.0 in Q4 2025 per MIRA's latest filing, from $562500.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $625000.0 in Q4 2025, with the low at $250000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 625,000.00 |
| Dec 31, 2025 | 625,000.00 |
| Sep 30, 2025 | 562,500.00 |
| Sep 30, 2025 | 562,500.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Mar 31, 2025 | 250,000.00 |